Gadoversetamide Pregnancy and Breastfeeding Warnings
Brand names: OptiMARK
Gadoversetamide Pregnancy Warnings
Gadoversetamide has been assigned to pregnancy category C by the FDA. Animal studies have revealed evidence of teratogenicity. There are no controlled data in human pregnancy. Gadoversetamide is only recommended for use during pregnancy when there are no alternatives and benefit outweighs risk.
Gadoversetamide Breastfeeding Warnings
There are no data on the excretion of gadoteridol into human milk. The manufacturer recommends that women should discontinue nursing and discard breast milk up to 72 hours after gadoversetamide administration.
See also
References for pregnancy information
- Product Information. OptiMARK (gadoversetamide). Mallinckrodt Medical Inc. 2010.
References for breastfeeding information
- Product Information. OptiMARK (gadoversetamide). Mallinckrodt Medical Inc. 2010.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
